Annual Report
Our Annual Report provides a wide range of information about our global business and how we are working, both within the company and in partnership with others, to meet complex healthcare challenges and make a meaningful difference for patients worldwide.
Latest press releases
- US Appeals Court issues a temporary injunction pending appeal against distribution of generic PULMICORT RESPULES
- 25 May 2013
- AstraZeneca Issues Update on Accelerated Oncology Pipeline in Advance of 2013 ASCO Annual Meeting
- 16 May 2013
- Taskforce meets to begin planning for future of Alderley Park
- 29 April 2013
- AstraZeneca PLC first quarter results 2013
- 25 April 2013
- AstraZeneca and BIND Therapeutics announce worldwide development and commercialisation agreement for cancer nanomedicine
- 22 April 2013
- AstraZeneca announces top-line results from OSKIRA-1 Phase III study of fostamatinib in rheumatoid arthritis
- 5 April 2013
- MedImmune, AstraZeneca’s biologics arm, acquires AlphaCore Pharma
- 3 April 2013
- US District Court rules one PULMICORT RESPULES® (Budesonide Inhalation Suspension) patent invalid and another patent not infringed
- 2 April 2013
- AstraZeneca settles litigation over CRESTOR patent
- 25 March 2013
Hear directly from our scientists on LabTalk, discussing how we're applying innovation to our scientific discovery.
